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ABSTRACT
Yin Yang 1 (YY1) is a critical transcription factor
controlling cell proliferation, development and DNA
damage responses. Retrotranspositions have
independently generated additional YY family
members in multiple species. Although Drosophila
YY1 [pleiohomeotic (Pho)] and its homolog
[pleiohomeotic-like (Phol)] redundantly control
homeotic gene expression, the regulatory contribu-
tions of YY1-homologs have not yet been examined
in other species. Indeed, targets for the mammalian
YY1 homolog YY2 are completely unknown. Using
gene set enrichment analysis, we found that
lentiviral constructs containing short hairpin loop
inhibitory RNAs for human YY1 (shYY1) and its
homolog YY2 (shYY2) caused significant changes
in both shared and distinguishable gene sets in
human cells. Ribosomal protein genes were the
most significant gene set upregulated by both
shYY1 and shYY2, although combined shYY1/2
knock downs were not additive. In contrast, shYY2
reversed the anti-proliferative effects of shYY1, and
shYY2 particularly altered UV damage response,
platelet-specific and mitochondrial function genes.
We found that decreases in YY1 or YY2 caused
inverse changes in UV sensitivity, and that their
combined loss reversed their respective individual
effects. Our studies show that human YY2 is
not redundant to YY1, and YY2 is a significant reg-
ulator of genes previously identified as uniquely
responding to YY1.
INTRODUCTION
Yin Yang 1 (YY1, d, NF-E1, UCRBP or CF1) is a
multifunctional zinc-ﬁnger transcription factor (1), and a
member of the Polycomb protein Group (PcG). PcG
proteins control the plasticity of the pluripotent state,
stem-cell development and maintenance of lineage-speciﬁc
gene-expression programs (2,3). They were ﬁrst
described in Drosophila as regulators of body segmenta-
tion patterns through their repression of homeotic (Hox)
gene expression (4). The PcG complex includes sev-
eral oncogenes including posterior sex combs (PSC—the
Bmi oncogene) and EZH2 (5). YY1 is the major
DNA-binding protein in the Polycomb complex (6),
and its ﬂy homolog is pleiohomeotic (Pho) (7). In
addition to their functions in polycomb repression, both
Pho and YY1 are the DNA-binding proteins in the INO80
DNA transcriptional-remodeling complex (8,9).
Independent retrotranspositions have given rise to YY1
homologs in many species that include pleiohomeotic-like
(Phol) in Drosophila (10) and Yin Yang 2 (YY2) in
mammals (11). Of note, Drosophila Phol is redundant
with pleiohomeotic in homeotic gene silencing since
double mutants show more severe mis-expression of
homeotic genes and more extreme developmental
phenotypes (10). On the other hand, a genome-wide
analysis of Pho and PhoL targets has not been performed,
nor have gene targets of YY2 been compared to those of
YY1.
In addition to its participation in polycomb and INO80
complexes, YY1 interacts with additional components of
transcriptional control (1). It was simultaneously dis-
covered as a regulator of ribosomal protein synthesis
(12), and as a key repressor of adenoviral oncogenesis
(13). In association with various cofactors, YY1 is
involved in transcription activation and repression (1),
histone modiﬁcation (14), chromatin remodeling (15),
DNA damage repair (9), as well as tumorigenesis
(16–18). YY1 knock-out causes embryonic lethality
(19,20), and development of several tissues is critically
dependent on YY1 including B lymphocytes, the axial
skeleton and neural progenitors (21–23). In addition, its
expression is needed to support cell-cycle proliferation
(20), and elements of this requirement have been
proposed to occur through interactions with p53 or E2F
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and DNA damage repair (9). YY1’s cis target sequence is
the tenth most common mammalian DNA-binding motif,
which is present in 2% of well annotated promoters (26).
Although a large number of genes have been proposed to
be regulated by YY1 (1), transcriptome analyses of YY1
knockout mice did not show signiﬁcant changes in mRNA
expression for most of these genes (20). This discrepancy
suggests that another transcription factor can compensate
for YY1 deﬁciency.
Two additional YY1-site-binding proteins have been
identiﬁed in mammals—YY2 and zinc-ﬁnger protein 42
(ZFP42, Rex-1) (11,27). Both share 95% identity in their
zinc-ﬁnger-binding regions with YY1, and their
DNA-binding targets are nearly identical to those of
YY1 (27,28). ZFP42 was described initially as Reduced
Expression in retinoic acid-induced embryonal carcinoma
cells (Rex-1) (29), which is an embryonic stem-cell marker
that controls embryonic stem-cell self-renewal (28,30,31).
It was actually the ﬁrst YY family member to be cloned,
but its expression levels are low in most cell lines (28). It
has therefore received much less attention than YY1. YY2
was recently identiﬁed in a homology screen (11). It
appears to be a recently transposed, but functional, tran-
scription factor that was inserted into the intron of
Mbtps2, which is undergoing rapid evolution in
mammals (32). YY2 and Rex1 largely share DNA-
binding motifs with YY1, although their aﬃnities and
speciﬁc target sequences diﬀer somewhat (27). The only
test of interaction between mammalian YY1 and YY2
suggests they antagonistically aﬀect reporter genes
carrying canonical YY1 cis target sequences (33).
Almost nothing is known about YY2- or ZFP42-regulated
genes, and their interactions with YY1 have not been
explored. Given the importance of YY1 in mammalian
development and carcinogenesis, we sought to deter-
mine whether YY2 or ZFP42 might contribute to the
functional complexity of YY1’s various roles in cellular
physiology.
Diﬀerences in individual genes identiﬁed using
standard DNA microarray analyses are often subtle;
therefore studies of coordinated changes in groups of
functionally related genes have attracted increasing
interest (34). Since the previous microarray study
that evaluated YY1 target genes in embryonic tissues did
not use gene set enrichment analyses (GSEA) (20),
we considered that GSEA might yield important infor-
mation about sets of YY1 target genes and their poten-
tial overlaps with other YY family target gene sets
(35–37). We therefore used lentiviral-expressed
shRNAs from the RNAi consortium (38) to systematically
reduce expression levels of YY1, YY2 and ZFP42 in a
model cell line (11). We then used microarray and
GSEA to identify relationships between their respec-
tive targets (35,37). Even though many gene sets were
altered in a similar manner by shYY1 and shYY2, here
we show that YY2 contributes to expression control
of several important genes and gene sets that diﬀer
from YY1.
MATERIALS AND METHODS
Plasmids and primer sequences
Lentiviral pLKO-shRNAs were obtained from
Sigma-Aldrich. The tracking numbers of the most
eﬀective shRNAs are TRCN0000019894 (YY1),
TRCN0000016494 (YY2), TRCN0000107810 (ZFP42)
and TRCN0000039642 (Myc). To replace the
puromycin-resistance gene in pLKO plasmids with
G418-resistance for combined knock down, an 827bp
fragment containing the neoR gene was ampliﬁed from
plasmid pCNH (39) with primers 50-TCA GGA TCC
AGG ATC GTT TCG CAT GAT TGA AC-30 and
50-TCA GGT ACC GAT GCA TGA GTC CCG CTC
AGA AGA ACT CG-30, digested by Kpn I and BamHI ,
and ligated to Kpn I/BamH I-treated pLKO- shRNA
plasmids. Plasmids pCEP4-FLAGYY1 and pCEP4-
HAYY2 were derived from pcDNA-FLAGYY1 and
pcDNA-FLAG/HAYY2 by PCR and ligation with
vector pCEP4. These two plasmids were used as standards
to measure endogenous YY1 and YY2 expression in
quantitative real-time polymerase chain reaction
(qRT-PCR). Double-stranded oligonucleotides used as
electrophoresis mobility shift assay (EMSA) probes were
based on an YY1-binding site in the eIF4E promoter
(50-CCA CAG TCG CCA TCT TAG A-30).
Cell culture and shRNA transduction
HeLa cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) supplemented with 10% fetal bovine
serum, maintained in 37 C incubators with 5% CO2.
OV90 ovarian cells, MDA-MB-468 breast cells, MCF7
breast cells, T47D breast cells and Raji B cells were
grown in conditions suggested by the ATCC.
pLKO-shRNAs were packaged in 293T cells following
the manufacturer’s standard protocol (Sigma-Aldrich).
Spent medium of 293T cells was collected at 24 and 48h
post-transfection, pooled and cleared through a 0.45-mm
syringe ﬁlter. To infect, HeLa cells were grown in six-well
culture plates in 2ml medium and 0.5ml of
lentivirus-containing medium was added. After 72h, cells
were selected and maintained in medium containing
2mg/ml of puromycin. To make combined shRNA
transfectants, this process was repeated but additionally
selected using 500mg/ml of Geneticin (G418) for dual
selections. MCF7 and T47D cells were similarly treated
to obtain stable transfectants to validate the HeLa cell
results. Stable transfectants were split once a week and
cells of <15 passages were used in all assays. To
perform MTT, spent medium was aspirated and cells
were incubated with 10ml of 5mg/ml thiazolyl blue
tetrazolium bromide (Sigma) and 20ml of 100mM
disodium succinic acid at 37 C for 3h, then with 130ml
of DMSO for 20min at room temperature. Absorbance
was measured in a plate reader at 550nm with a 620nm
reference ﬁlter.
Microarray and gene set enrichment analysis
Total RNA was prepared by Trizol reagent (Invitrogen).
Ten micrograms of RNA were used to prepare probes
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genome arrays. Probes were synthesized using
Aﬀymetrix One-Cycle target labeling and control
reagents and the Enzo BioArray high yield RNA tran-
script labeling kit. Raw data were generated by the
GeneChip Scanner 3000 and its bundled software. Each
analysis was performed using triplicate samples. Raw data
were normalized using the GeneChip Operating System
algorithm and the resulting matrix table was ﬁltered to
remove absent data points. While this ﬁlter may
decrease our discovery of more robust changes, it should
signiﬁcantly decrease false-positive discoveries. The
resulting matrix tables were uploaded using the desktop
module for Gene Set Enrichment Analysis (Broad
Institute) (35,37). We analyzed curated, motif and
computational data sets using 1000 gene set permutations.
The results were downloaded and compiled to compare
the eﬀects of shYY1, shYY2 and the combination of
shYY1 and shYY2 to cells expressing the LKO vector
control.
cDNA synthesis and qRT-PCR
Two micrograms of total RNA were used to make cDNA.
Prior to reverse transcription, samples were ﬁrst treated
with one unit of DNase I for 15min at room temperature
to remove residual genomic DNA. Following a 5-min 65 C
incubation to inactivate DNase I, samples were annealed
with oligo(dT) and reverse-transcribed using a Superscript
III First-strand cDNA Synthesis Kit (Invitrogen) follow-
ing the manufacturer’s standard protocol. The resulting
cDNAs were diluted 25-fold and 10ml samples were
mixed with SYBR-Green Supermix (Bio-Rad) and
0.4mM of each primer in a 25-ml PCR reaction and
thermocycled in the Bio-Rad MyiQ single color real time
PCR detection system. We designed primer sets for 57 can-
didate genes chosen for their responsiveness to shYY1,
shYY2 or their combination (Supplementary Table S1).
We then compared the average of every individual
microarray set for the 57 genes to the average of the
qRT-PCR results (n=3) for each gene in a Pearson cor-
relation analysis (Sigmastat software).
Western blot and immunoprecipitation
For immunoblotting, cells were lysed using NP40 lysis
buﬀer (50mM Tris, pH 8.0, 0.42M NaCl, 0.5% NP40,
2mM EDTA) supplemented with fresh complete protease
inhibitor cocktail tablets (Roche) for 20min on ice. Lysates
were cleared by centrifugation at 14000rpm for 10min and
protein concentrations determined by Bio-Rad protein
assays. Equal amounts of lysates were fractionated on
SDS–polyacrylamide gel electrophoresis (PAGE) and
immunoblotted with YY1 antibody (Santa Cruz sc-281)
at 1:1000 dilution, or 1:1000 thrombospodin-1
(sc-59887), 1:100 CD-36 (sc-9154) and 1:5000 actin
antibodies (Chemicon). To perform immunoprecipitation,
cells were grown in 10-cm tissue culture dishes. Following
incubation of the monolayer in methionine- and cysteine-
free medium (Cellgro) plus 5% dialyzed FBS (Hyclone) for
3h, 500mCi
35S-methionine/cysteine (Perkin Elmer) was
added and incubated for 3h at 37 C, 5% CO2. Cells were
rinsed once with cold PBS and RIPA buﬀer (150mM
NaCl, 5mM EDTA, 50mM Tris, pH 7.4, 0.05% NP-40,
1% deoxycholic acid, 1% Triton X-100, fresh complete
protease inhibitor cocktail tablets) was added for 10min
on ice. The lysates were pre-cleared by incubating with 5mg
non-speciﬁc goat serum (Santa Cruz) plus 20ml Protein-G
Agarose (Santa Cruz) for 30min at 4 C. The beads were
removed by centrifugation at 2500rpm 5min at 4 C, and
the supernatant treated with 10mg of each anti-YY2
antibody (sc-47637 and sc-47635). Protein-G Agarose
was added to the preparation and agitated overnight at
4 C. Beads were then rinsed with RIPA buﬀer, and
boiled in 1 Laemmli electrophoresis buﬀer for 2min
to isolate the immunoprecipitated proteins. The labeled-
immunoprecipitated proteins were then separated using
standard 10% SDS–PAGE, and autoradiographed.
Eletrophoretic mobility shift assay
To prepare nuclear extracts, cells were washed with PBS,
lifted from dishes by scraping, and incubated in hypotonic
buﬀer (10mM HEPES, pH 7.9, 10mM KCl, 1.5mM
MgCl2, 0.5mM DTT). Nuclei were isolated by
Dounce-homogenization and collected by centrifugation
at 14000r.p.m. for 20min. Proteins were extracted from
pellets by high-salt buﬀer (20mM HEPES, pH 7.9, 0.42M
NaCl, 1.5mM MgCl2, 0.2mM EDTA, 0.5mM DTT), and
dialyzed with storage buﬀer (20mM HEPES, pH 7.9,
100mM KCl, 0.2mM EDTA, 20% glycerol, 0.5mM
DTT). All buﬀers were supplemented with fresh protease
inhibitors and all procedures were performed either on ice
or at 4 C. Double-stranded oligonucleotides were
end-labeled with
32P. To perform DNA binding, 5mg
nuclear extracts were incubated with 5 10
4cpm of
probes in the presence of 10mg/ml poly(dIdC) in binding
buﬀer (10mM Tris, pH 7.5, 50mM NaCl, 1mM DTT,
1mM EDTA, 5mM MgCl2, 5% glycerol). After 5min of
incubation, mixtures were fractionated at 4%
polyacrylamide/0.5 TBE at 280V, 4 C for 1h.
UV irradiation
Two thousand cells per well were seeded in 96-well tissue
culture plates and grown overnight. The four cell lines to
be tested (LKO vector, LKO-shYY1, LKO-shYY2 and
LKO-shYY1 and two combined) were seeded within indi-
vidual plates at interval rows to avoid exposure and mea-
surement variations. Plates were placed on the glass plate
of a UVP Bioimaging System. A stack of microplate ﬁlms
(MJ Research) was inserted under the 96-well plates.
These ﬁlms reduced the UV permeability so that
exposure time could be precisely controlled. Cells were
irradiated from 10 to 90s. Cells were incubated for
6days after irradiation and measured by MTT assays.
All readings were normalized to an unexposed plate.
RESULTS
YY1 and YY2 expression
Studies of the YY family proteins have to date failed to
address their interactions, despite strong homology in
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both YY2 and ZFP42 are expressed retrotransposons that
have recently appeared in the mammalian genome. Since
YY2 was initially described in HeLa cells, we ﬁrst
compared its expression levels to YY1 levels in those
cells. YY1 was present at 751±0.1 mRNA copies and
YY2 was present at 10.3±0.7 copies per nanogram
total RNA. ZFP42 levels were at the border of
detectability in HeLa cells. We then compared YY1 and
YY2 mRNA copy numbers in ﬁve additional cell lines to
assess their relative expression of YY1 and YY2
(Figure 1A). Notably, YY1 and YY2 levels varied little
between cell lines and we consequently used HeLa cells for
further studies.
We expressed four to ﬁve independent lentiviral shRNA
constructs for each of the three YY family members and
identiﬁed the transduced cells exhibiting the strongest
knock down eﬀect for each gene. We compared the
knock down eﬀects of the strongest shRNA on its
targeted mRNA and on each of the other YY family
members. The three shRNAs had minimal eﬀects on
other YY family members (Figure 1B). We also assessed
their eﬀects on c-myc since it is a known YY1-regulated
gene (40). Of note, both the 90% knock down of YY1 and
the 50% knock down of YY2 had similar net eﬀects on
Myc gene expression, which decreased by 44% in
shYY1-expressing cells, and 38% in shYY2-expressing
cells. Thus, despite diﬀering mRNA levels of YY1 and
YY2, and the 2-fold diﬀerence in knock down eﬀects,
myc mRNA decreases were very similar in both knock
downs, a strong argument for a signiﬁcant contribution
of YY2 to transcriptional regulation. The decreases in myc
mRNA are consistent with YY1’s reported role as an
initiator-binding transcription factor for the cognate site
on the Myc promoter and suggest that YY2 shares the
same function.
Downregulation of YY1 and YY2 proteins were also
observed in response to the shRNA constructs.
Immunoblots showed signiﬁcantly reduced YY1 protein
in shYY1-treated cells, but no change in pLKO vector-,
shYY2- or shZFP42-expressing cells (Figure 1C).
Correspondingly, nuclear extracts from shYY1-treated
cells showed loss of binding activity to the YY1-cognate
site (Figure 1D). Endogenous YY2 was not detectable by
western blot due to either low protein levels and/or weak
YY2 antibody activities. Two Santa Cruz antibodies
Figure 1. Altered expression of YY1 and YY2. (A) Copy numbers of YY1 and YY2 mRNAs in total RNA extracted from HeLa cells were
compared with those in ﬁve other cell lines. Copy numbers were derived from qRT-PCR using plasmids pCEP4-FLAGYY1 and pCEP4-HAYY2
to provide standards. The YY2/YY1 copy number ratio was compared to that of HeLa and is plotted for each cell line. Standard deviations (SD) are
shown, n=3. The indicated cells are OV90, HeLa, MDA-MB-468 (468), MCF7, T47D and Raji cells. (B) shRNAs decreased YY family and Myc
gene expression. The z-axis plots fold change between LKO-vector expressing control cells and the indicated shRNA identiﬁed along the x-axis. The
y-axis identiﬁes the mRNA assayed using qRT-PCR. (C) Western blots revealed reduced expression of YY1 in shYY1-treated cells (lane 4), but not
in pLKO-, shZFP42- and shYY2-treated cells (lanes 2, 3, 5). Lane 1, MagicMark protein ladder (Invitrogen). (D) Electrophoretic mobility shift assay
indicated loss of binding activity to the YY1-binding element in shYY1 treatment. Lane 1, pLKO vector treatment; Lane 2, shZFP42 treatment;
Lane 3. shYY1 treatment; Lane 4. shYY2 treatment. (E) Immunoprecipitation of YY2 from
35S-methionine incorporated cells. Lanes 1 and 2, HeLa
cells treated with control pLKO vectors; Lanes 3 and 4, HeLa cells treated with shYY2. Lanes 1 and 3, lysates were incubated with non-speciﬁc goat
serum as antibody controls. Lanes 2 and 4, lysates were incubated with anti-YY2 antibodies. The indicated YY2-speciﬁc band migrates just under
60kD, as expected.
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were used to immunoprecipitate 35S-radiolabeled cells
(Figure 1E). We identiﬁed reduced amounts of a protein
migrating just under 60kDa corresponding to YY2
protein in shYY2-treated cells, along with multiple
co-precipitated bands.
Gene set enrichment analysis and quantitative real-time
polymerase chain assessment of array performance
We performed gene-expression proﬁling to gain perspec-
tive on the relationships between genes regulated by the
YY family members. RNA was harvested for proﬁling and
analyzed using Aﬀymetrix human genome U133 Plus 2.0
chips as described in methods. While knock down of YY1
and YY2 caused signiﬁcant expression changes as assessed
by statistical analysis of microarrays (SAM) (41), knock
down of ZFP42 did not (Supplementary Figure S1). We
therefore focused the remainder of our analyses on YY1
and YY2 since the lack of signiﬁcance in array data for the
ZFP42 knock downs was likely due to its borderline
expression in the parental cells.
In general, genes responded similarly to YY1 and YY2
knock down in expression microarrays (Figure 2A). To
identify the sets of genes that responded to decreased
YY1 expression and/or decreased YY2, we applied gene
set enrichment analysis (GSEA) using compiled gene sets
from the Broad Institute (34,35,37,42) (Table 1–3). GSEA
tests for the enrichment of genes in rank-ordered gene lists
based on their relatedness to observed changes in test
samples. Enrichment scores (ES) are calculated as a
running sum statistic, which increases for every gene
Figure 2. Comparison of array versus qRT-PCR measurements of mRNA changes in cells expressing shYY1, shYY2 and shYY1/2. (A) Shown is a
scatter plot comparing the eﬀects of shYY1 to those of shYY2 in microarray experiments. We show mRNA signals that changed 2-fold or greater in
the respective knock down cells from control cell levels. The x-axis plots the log of the change in the array signal comparing control pLKO cells to
shYY1-expressing cells; the y-axis plots the log of the change in the arrays from control cells to shYY2-expressing cells for each probe. (B–D)W e
then developed primer sets for qRT-PCR analyses for 57 mRNAs identiﬁed from our microarray data as showing signiﬁcant responses to knock
down of YY1, YY2 and/or their combined knock down. (B) We show a scatter plot comparing microarray (x-axis) and qRT-PCR measurements
(y-axis) of the mean fold change in expression of each gene comparing LKO-transduced control cells and cells expressing the shYY1 construct. The
array data shows the mean for array data from all probe sets for each gene. The qRT-PCR shows the mean for three determinations for each gene.
A Pearson correlation analysis was performed comparing the mean qRT-PCR result and the mean for each individual probe set for each gene.
Shown is the Pearson correlation coeﬃcient and the corresponding P-value. (C) We show a similar scatter plot as in A but we compare the array and
qRT-PCR results for changes between LKO-control transduced cells and shYY2-expressing cells. (D) We show a similar scatter plot comparing
control LKO-transduced cells and cells expressing both shYY1 and shYY2.
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gene set and decreases for every gene change absent from
those sets (35,37). The statistical signiﬁcance of the ES
compares the measured ES to a calculated score
assuming a null distribution. False determination rates
(FDRs) calculate the probability that a given ES repre-
sents a false positive in multiple hypothesis testing. As
shown for the individual genes, similar gene sets were
aﬀected by shYY1 and shYY2. Consequently, we sought
to determine whether combined decreases in both YY1
and YY2 would have additive eﬀects by expressing both
shRNAs together using combined G418 and puromycin
selection. We identiﬁed cells that expressed both the
shYY1 and the shYY2 at the same levels when they
were combined as when they were individually expressed
(data not shown).
We validated the microarray data by comparing expres-
sion changes in microarrays to expression changes deter-
mined by qRT-PCR in the various knock down cell lines.
We performed qRT-PCR to evaluate a total of 57
mRNAs, choosing 7–13 individual genes from each gene
set that best represented changes occurring within those
sets (Supplementary Table S2). Shown are scatter plots
comparing the array fold change versus the qRT-PCR
fold change for the shYY1, shYY2 and shYY1-shYY2
cells, comparing the mean array and qRT-PCR data for
all 57 mRNAs (Figure 2B and C). Our array and
qRT-PCR values were highly correlated using Pearson
tests for signiﬁcance.
Many gene sets were altered in a similar manner by
shYY1 and shYY2 (Table 1). The maximum ES for any
individual gene set was found for ribosomal protein
mRNAs, and enrichment plots are shown for shYY1
(Figure 3A) and shYY2 (Figure 3B). We also show histo-
gram plots that compare expression changes for 198
ribosomal protein mRNAs to changes for all other
mRNAs, which demonstrate that the YY1 knock down
generally increased ribosomal protein mRNA levels
Table 1. Gene sets responding to both shYY1 and shYY2 using gene set analysis
NAME YY1 NES YY1
NOM
P-value
YY1
FDR
Q-value
NAME YY2 NES YY2
NOM
P-value
YY2
FDR
Q-value
Growth
RIBOSOMAL PROTEINS 3.508 0.000 0.000 RIBOSOMAL PROTEINS 2.685 0.000 0.000
MORF TPT1 3.432 0.000 0.000 MORF TPT1 2.822 0.000 0.000
GCM TPT1 3.364 0.000 0.000 GCM TPT1 2.783 0.000 0.000
GNF2 TPT1 3.267 0.000 0.000 GNF2 TPT1 2.735 0.000 0.000
GNF2 DAP3 2.674 0.000 0.000 GNF2 DAP3 2.327 0.000 0.000
GNF2 EIF3S6 3.307 0.000 0.000 GNF2 EIF3S6 2.629 0.000 0.000
Myc
SCHUMACHER MYC UP  2.141 0.000 0.021 IRITANI ADPROX DN 2.352 0.000 0.000
LEE MYC UP 1.800 0.000 0.060 IRITANI ADPROX VASC 2.286 0.000 0.000
Other transcription factors
V$AR 02  1.583 0.026 0.326 V$AR 02  1.422 0.075 0.596
V$HOX13 01  1.422 0.075 0.657 V$HOX13 01  1.497 0.052 0.542
KTGGYRSGAA UNKNOWN  1.797 0.004 0.169 KTGGYRSGAA UNKNOWN  1.543 0.013 1.000
MORF JUND 2.984 0.000 0.000 MORF JUND 2.340 0.000 0.000
DNA damage
ATRBRCA PATHWAY  1.966 0.000 0.036 ATRBRCAPATHWAY  1.591 0.034 0.608
Growth factors
IFN BETA GLIOMA DN 2.182 0.000 0.001 IFN BETA GLIOMA DN 2.520 0.000 0.000
UV response
UVB NHEK1 C1 2.309 0.000 0.001 UVB NHEK1 C1 2.697 0.000 0.000
UVB NHEK2 UP 1.854 0.000 0.056 UVB NHEK2 UP 2.488 0.000 0.000
Tissue type
AGED MOUSE HYPOTH UP 1.725 0.002 0.100 AGED MOUSE HYPOTH UP 2.109 0.000 0.001
Miscellaneous
MORF ACTG1 3.455 0.000 0.000 MORF ACTG1 2.857 0.000 0.000
MORF NPM1 3.320 0.000 0.000 MORF NPM1 2.811 0.000 0.000
GNF2 ST13 3.147 0.000 0.000 GNF2 ST13 2.415 0.000 0.000
MORF NME2 3.024 0.000 0.000 MORF NME2 2.893 0.000 0.000
GCM NPM1 2.750 0.000 0.000 GCM NPM1 2.502 0.000 0.000
GNF2 GLTSCR2 2.643 0.000 0.000 GNF2 GLTSCR2 2.162 0.000 0.000
GCM ACTG1 2.353 0.000 0.000 GCM ACTG1 2.294 0.000 0.000
NES are calculated by a running sum statistic, which increases for gene changes matching equivalent changes in compiled gene sets and decreases for
gene changes absent from sets, normalized to the size of the set. The statistical nominal P-value (NOM P-value) compares the measured NES to a
calculated null distribution. The false determination rate (FDR) is the estimated probability that a given ES represents a false positive given multiple
hypotheses being tested. The molecular signature set annotations are found at: http://www.broad.mit.edu/gsea/msigdb/annotate.jsp.
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Name Type Size YY2 ES YY2 NES YY2 NOM
P-value
YY2 FDR
Q-value
UV damage
UVB NHEK1 UP Gene set 123 0.485 2.171 0.000 0.000
UVB SCC UP Gene set 82 0.520 2.147 0.000 0.001
UVC HIGH D2 DN Gene set 36  0.420  1.547 0.020 0.600
Mitochondrial function
MOOTHA VOXPHOS Gene set 75 0.629 2.558 0.000 0.000
ELECTRON TRANSPORT CHAIN Gene set 92 0.561 2.376 0.000 0.000
Tissue type
PLATELET EXPRESSED Gene set 27 0.663 2.185 0.000 0.000
GNATENKO PLATELET UP Gene set 36 0.654 2.282 0.000 0.000
GNATENKO PLATELET Gene set 36 0.654 2.299 0.000 0.000
Transcription factors
KRCTCNNNNMANAGC UNKNOWN Cis 20 0.645 1.943 0.000 0.032
Growth factors
EGF HDMEC UP Gene set 38 0.598 2.131 0.000 0.001
Miscellaneous
ET743 SARCOMA UP Gene set 57 0.540 2.105 0.000 0.001
GUO HEX DN Gene set 40 0.602 2.193 0.000 0.000
PROTEASOME PATHWAY Gene set 21 0.708 2.175 0.000 0.000
MORF AP2M1 Computational 214 0.437 2.121 0.000 0.000
MORF ATOX1 Computational 79 0.540 2.218 0.000 0.000
MORF ERH Computational 113 0.482 2.132 0.000 0.000
MORF PRDX3 Computational 84 0.519 2.160 0.000 0.000
MORF RAD21 Computational 177 0.419 1.991 0.000 0.001
MORF RAN Computational 263 0.484 2.404 0.000 0.000
CTGAGCC,MIR-24 cis 140  0.417  1.976 0.000 0.027
As in Table 1 except that type refers to the type of database used, size identiﬁes the number of genes tested in the indicated set and the ES is the
non-normalized enrichment score, without normalization to the size of the dataset.
Table 2. Gene sets responding to shYY1 using gene set analysis
NAME Type SIZE YY1 ES YY1 NES YY1 NOM P-value YY1 FDR Q-value
E2F
REN E2F1 TARGETS Gene set 37  0.553  2.004 0.000 0.042
CELL CYCLE CHECKPOINT Gene set 23  0.554  1.743 0.004 0.142
Growth
MORF EIF4A2 Computational 136 0.491 2.205 0.000 0.000
MORF EIF4E Computational 83 0.483 2.038 0.000 0.011
Other transcription factors
SANSOM APC LOSS5 UP Gene set 63  0.498  2.010 0.000 0.055
GAY YY1 DN Gene set 161  0.391  1.846 0.000 0.079
Tissue type
HYPOPHYSECTOMY RAT UP Gene set 26 0.698 2.173 0.000 0.000
STRIATED MUSCLE CONTRACTION Gene set 15 0.712 2.004 0.000 0.015
MUNSHI MM UP Gene set 56 0.536 1.938 0.000 0.008
Miscellaneous
CMV IE86 UP Gene set 49  0.522  1.990 0.000 0.038
MOREAUX TACI HI IN PPC UP Gene set 70 0.479 1.967 0.000 0.043
PARK MSCS DIFF Gene set 27 0.584 1.926 0.000 0.030
GCM PSME1 Computational 83 0.492 2.063 0.000 0.001
GNF2 BNIP3L Computational 44  0.489  1.819 0.000 0.042
GNF2 CKS1B Computational 37  0.536  1.936 0.000 0.021
GNF2 FBL Computational 145 0.593 2.710 0.000 0.000
GNF2 FGR Computational 15 0.662 1.879 0.004 0.004
GNF2 MBD4 Computational 24 0.598 1.932 0.002 0.003
GNF2 NPM1 Computational 70 0.498 2.024 0.000 0.001
GNF2 RFC3 Computational 41  0.518  1.911 0.000 0.016
GNF2 RFC4 Computational 60  0.486  1.916 0.000 0.019
As in Table 1 except that type refers to the type of database used, size identiﬁes the number of genes tested in the indicated set and the ES is the
non-normalized enrichment score, without normalization to the size of the dataset.
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in response to shYY1 than to shYY2 (Figure 3D),
although this comparison also reﬂects the 90% decrease
in YY1 expression versus the 50% decrease in YY2 in
their respective knock down cells. A comparison of
shRNA eﬀects for ribosomal protein mRNAs generally
shows that shYY1 and shYY2 both increased most
ribosomal protein mRNAs (Figure 3A). However, unlike
Pho and Phol whose combined mutations caused additive
eﬀects on homeotic gene expression, the combination of
shYY1 and shYY2 was non-additive for ribosomal
protein mRNAs (Figure 3E).
YY1 and YY2 diﬀerential functions
While YY1’s global eﬀects on cell division, mitosis and
DNA damage repair have been well-described, no
YY2-speciﬁc functions or target genes have been
identiﬁed. In order to determine whether YY1 and YY2
have any unique target genes, we examined genes most
altered by shYY1 and shYY2 in microarray data and
validated them using qRT-PCR (Figure 4). We identiﬁed
genes most perturbed by shYY1 (Figure 4A and B), most
perturbed by shYY2 (Figure 4C and D), most decreased
by both shYY1 and shYY2 (Figure 4E and F), most
Figure 3. shYY1 and shYY2 eﬀects on ribosomal protein mRNA expression. Gene Set Enrichment Analysis (GSEA) determines whether a deﬁned
set of genes shows concordant changes between two biological states. Enrichment scores (ES) are calculated by a running sum statistic, which
increases for gene changes matching equivalent changes in compiled gene sets and decreases if changes were not seen for the given gene set. The
enrichment plots shown here plot the concordance of ribosomal proteins mRNA changes with the ‘Ribosomal_Protein’ curated data set at:
http://www.broad.mit.edu/gsea/msigdb/annotate.jsp. Shown are plots for shYY1 versus the LKO-vector-expressing cells (A). The enrichment score
increments for every gene whose expression changes in response to shYY1 that is a ribosomal protein gene (hits). In this case, nearly all of the
ribosomal protein mRNAs evaluated in these arrays increase in cells targeted by shYY1. In (B), cells expressing shYY2 show a similar response to
YY2 knock down, although to a somewhat lesser extent. (C and D) Shown are histogram plots for the average change in the microarray signal for
each of 198 ribosomal mRNAs compared with all other mRNA signals in the microarrays. The count (y-axis) shows the number of mRNAs
deviating to the extent shown on the x-axis, which is the average deviation between the signal in the shYY arrays compared to the LKO vector
control RNAs. [shYY1 and shYY2 eﬀect shows fold change (ln) from control for the indicated bins.] The red histograms (C) show shYY1-induced
changes and the blue histograms are for shYY2-induced changes (D). For the ribosomal protein mRNAs the y axes are on the right side of the plots.
The grey histograms depict changes in all non-ribosomal protein mRNAs; their corresponding counts are in black on the left y axes. (E) qRT-PCR
measurements of shYY1 and shYY2 eﬀects on individual ribosomal protein mRNAs. We used qRT-PCR to evaluate the changes in 12 ribosomal
mRNAS. Error bars demonstrate standard deviations, n=3.
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increased by shYY1 while decreased by shYY2 (Figure 4I
and J) and vice versa (Figure 4K and L). Our array data
were generally conﬁrmed by the qRT-PCR results as
shown in Figure 2B–D.
The E2F-related gene set contains YY1 targets
We identiﬁed gene sets responding more to shYY1 than to
shYY2 using GSEA (Table 2). The most signiﬁcant YY1
target sets were those involved in cell-cycle regulation,
including an E2F target set (43) (Figure 5A and B).
Previous reports of combinatorial interactions between
YY1 and E2F (24,44) and its known eﬀects on cell prolif-
eration (20) validate our approach since YY1 has
previously been shown to alter E2F targets. We could
detect little eﬀect of the shYY2 on these genes, as shown
in histogram plots of mRNA changes (Figure 5C and D).
To test the reproducibility of the shYY1 eﬀects, we
compared cell proliferation in cells transduced with all
ﬁve shYY1 constructs available from the RNAi consor-
tium. We plotted the cell density on Days 6, 7 and 8 after
plating for each of the ﬁve knock down pools with respect
to the levels of YY1 mRNA in each of the ﬁve pools. We
found that cell proliferation decreased incrementally with
decreasing YY1 levels (Figure 6A). We then tested the
eﬀects of shYY2 in proliferation assays using the most
eﬀective shYY2 knock down cells. Surprisingly, shYY2
increased proliferation. Moreover, when shYY2 was
combined with shYY1, the shYY2 reversed shYY1
eﬀects returning cells to a proliferation rate corresponding
to the normal control cells (Figure 6B). Thus, we found
that YY1 and YY2 actually serve antagonistic functions in
cell proliferation. qRT-PCR assays generally conﬁrmed
the microarray results in HeLa cells (Figure 6C). We
therefore tested the eﬀects of shYY1, shYY2 and
shYY1/2 on three candidate genes in T47D and MCF7
cells to evaluate the reproducibility of their eﬀects
(Figure 6D and E). CDK6 and c-myc were down-
regulated by both shYY1 and shYY2 in all cell lines,
whereas polo-like kinase 4 (PLK4) was downregulated
by shYY1, and upregulated by shYY2 in all three cell
lines.
Figure 4. YY1- and YY2-speciﬁc target genes identiﬁed by microarrays were validated by qRT-PCR. (A), (C), (E), (G), (I), (K) were derived from
microarray; panels (B), (D), (F), (H), (J), (L) depict qRT-PCR results plotted as fold change in mRNA levels between shRNA-expressing and control
vector-expressing cells. The mRNAs assayed are identiﬁed by their gene names along the x axes of each plot, including measurements of YY1 and
YY2 mRNAs. Columns graph the fold-change for the identiﬁed genes in cells expressing shYY1 (light gray bars), cells expressing shYY2 (open bars)
and cells expressing shYY1/2 (dark gray bars). Error bars=SD, n=3. (A), (B) Genes most aﬀected by shYY1. (C), (D) Genes most aﬀected by
shYY2. (E), (F) Genes most downregulated by shYY1 and shYY2. (G), (H) Genes most upregulated by shYY1 and shYY2. (I), (J) Genes increased
by shYY1 but decreased by shYY2. (K), (L) Genes decreased by shYY1 but increased by shYY2.
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To identify potential YY2-speciﬁc functions, we examined
gene sets especially aﬀected by shYY2 in GSEA and found
that ultraviolet irradiation (UV) damage is potentially
targeted more by YY2 than YY1 (Table 3). YY1 knock
down has previously been reported to sensitize UV
response as part of its associations with the INO80
chromatin-remodeling complex (9). Thus, our ﬁnding of
stronger eﬀects for YY2 for some UV damage response
expression sets was important. Two UV gene sets were
particularly aﬀected by shYY2 (45) (Figure 7A and B).
The histogram comparison of shYY1 and shYY2 eﬀects
on these genes conﬁrmed a more prominent shYY2 eﬀect
than shYY1 (Figure 7C and D). The diﬀerential eﬀects of
shYY1 and shYY2 were further demonstrated by analysis
of cell survival after UV irradiation. Upon exposure to
UV, shYY1 decreased the surviving fraction whereas
shYY2 increased it. When the two shRNAs were
co-expressed shYY2 reversed shYY1’s eﬀects
(Figure 8A) normalizing the surviving fraction at each
dose.
Within our list of target genes, we were intrigued to note
that thrombospondin (THBS1) was one member of the
UV gene set, which was known to respond to UV
exposure and enhance repair (46,47). We also noted that
the thrombospondin receptor CD36 is a prominent
YY2-responsive gene (Table 4, Figure 4K and L) (48).
To conﬁrm the functional relevance of our RNA
analyses for these particular targets, we assessed protein
levels of CD36 and thrombospondin (Figure 8B). As
found for its mRNA, thrombospondin protein was
decreased by shYY1 and shYY1/2, but not by shYY2
alone, which corresponds to the increased UV sensitivity
of the shYY1-expressing cells. As found in our qRT-PCR
results, CD36 protein was decreased by shYY1 and
increased by shYY2. Importantly, combining shYY1
and shYY2 caused an increase in CD36 compared with
shYY1 alone (Figure 8B, CD36 lanes 4 versus 2 and 3
versus 1). This change corresponds to the normalization
of the UV response in cells expressing both shYY1 and
shYY2. We validated several additional array results
for genes in the UV-induced gene set using qRT-PCR
measurements (Figure 8C). Finally, we tested the
reproducibility of three of these candidate genes (APS4,
thrombospondin 1 and CDC2) in additional cell lines. We
found that their responses were similar in T47D, MCF7
and HeLa cells.
DISCUSSION
Although gene duplication is thought to be the single most
powerful factor in evolution (49), the retrotransposition of
YY1-like/Pho-like genes presents an intriguing alternative
case of convergent evolution (27,32). Processed copies of
genes have emerged at the constant rate of 1 gene every 2
million years in Drosophila and primates (50). Compared
with point mutations, retrotransposition is a rapid evolu-
tionary process, which is a signiﬁcant source of new
coding sequences in gene evolution (51). The origin and
signiﬁcance of YY1 homologs may be an important
example of this evolution (52). The parent genes YY1
and Pho consist of ﬁve exons encoding highly homologous
domains. In contrast, Phol and YY2 are encoded by a
single exon each. Notably, YY2 is located in the ﬁfth
Figure 5. shYY1 and shYY2 target E2F-regulated mRNAs. (A and B) Shown are enrichment plots for two E2F target data sets that were most
signiﬁcantly aﬀected by shYY1. The datasets included E2F targets from Ren et al. (43) and a curated set of cell-cycle genes. No plots are shown for
shYY2 since it did not alter either E2F or cell-cycle sets. (C and D) Histograms demonstrating shYY1 and shYY2 eﬀects on E2F target gene mRNAs
were plotted as described for the ribosomal protein mRNAs. C was plotted as described for 3C, and D was plotted as described for 3D.
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Peptidase, Site 2 (Mbtps2) of placental mammals but not
other vertebrates, and its retrotransposition is a recent
event in evolution (32). Phol and YY2’s sequences are
also evolving more rapidly than YY1’s. Genetic analysis
shows that Pho and Phol serve redundant roles in
homeotic control in ﬂies (10), whereas reporter constructs
suggest that YY1 and YY2 can be antagonistic when
over-expressed (33). Why convergent selection for an
alternative YY1-like-coding sequence has occurred
throughout evolution is intriguing and suggests that the
alternative YY1-like proteins serve important regulatory
functions that balance and modulate potent YY1 eﬀects.
Here we show that YY2 indeed contributes to overall
gene-expression control.
A previous microarray study evaluated YY1 disruption
in mouse embryonic ﬁbroblasts, and identiﬁed YY1
targets (20). Importantly, our GSEA found that the gene
set containing those targets in ES cells also responded to
shYY1-knock downs in HeLa cells (Table 1), validating
our approach. However, our YY1 and YY2 knock downs
had their largest eﬀects on ribosomal protein genes, which
have not been noted in YY1 studies subsequent to its
initial discovery. Transcriptional control elements are
tightly conserved across all ribosomal protein genes (53).
A highly conserved downstream-binding site (d) was
found in the earliest studies of ribosomal protein pro-
moters, which was then shown to be the binding site for
the factor that is now known as YY1 (12,54–58).
Ribosomal protein genes have not emerged in subsequent
analyses of YY1’s functions as critical targets, so our
shRNA/GSEA strategy is the ﬁrst to re-identify this
previously described function for YY1. Both YY1 and
YY2 work mainly as repressors of ribosomal gene
Figure 6. shYY1 and shYY2 altered cell proliferation rates. (A) Cell-proliferation rates correlated with YY1 expression level. Shown are cell densities
(MTT OD) obtained on the indicated days versus the YY1 mRNA levels produced by each of ﬁve shYY1 vectors and the control vector. YY1
expression levels measured by qRT-PCR are plotted as fold change from the LKO vector control as [YY1]. Points for the various constructs were
plotted using a linear regression plot to show the dose eﬀect of YY1 loss versus the cell density achieved on each day. Error bars represent standard
error of means (SEM), n=16. All diﬀerences were signiﬁcantly diﬀerent by t-test. (B) Cell proliferation rates for cells expressing shRNA constructs.
The cell densities achieved on the indicated days are plotted as the MTT OD value. Error bars=SEM, n=24. Again diﬀerences were statistically
signiﬁcant on Days 7, 8 and 9 by t-test. (C) Fold change in mRNAs for selected E2F target genes aﬀected by shYY1 and shYY2 were determined by
qRT-PCR. Error bars represent SEM, n=3. (D) T47D cells were transduced with the shYY1, shYY2 and combined shYY1 and shYY2 vectors.
Gene-expression changes were determined using qRT-PCR by evaluating the fold-change in expression for three candidate genes comparing the
knock down cells to control T47D cells transduced with the LKO vector alone. Shown are the mean and SEM, n=3.(E) MCF7 cells were analyzed
using qRT-PCR as described for the T47D cells and eﬀects on the same three candidate target genes are graphed.
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to note that combined loss of both factors had no additive
eﬀects on their targets—a substantially diﬀerent situation
from Pho and Phol in ﬂies.
Having established that YY1 and YY2 functions were
non-additive for ribosomal gene expression, we then
explored potentially diﬀerent or antagonistic functions
for other gene sets. Our shRNA/GSEA strategy agreed
with other studies that E2F and cell proliferation are sig-
niﬁcant targets of YY1 (Table 2, Figure 5). We then
analyzed the eﬀects of shYY2 and combined shYY1/2
on cell proliferation and E2F target genes (Figure 6).
Notably, YY2 downregulation actually enhanced prolifer-
ation in contrast to shYY1’s known eﬀects on E2F func-
tions and proliferation (24,25). In combination with YY1
knock down, decreased YY2 expression then normalized
cell proliferation. This clear demonstration of antagonism
on a signiﬁcant cellular process shows that YY2 can serve
important roles diﬀerent from those of YY1. Moreover,
YY1 and YY2 had clearly distinctive eﬀects on PLK4
and on an important cell-cycle regulator, CDKN2B
(p15INK4B).
We further explored YY2 responsive gene sets and
discovered that UV responsive genes include YY2
targets that were not identiﬁed as YY1 targets.
Importantly, YY1 participates in homologous recombina-
tion DNA repair (HRR) as a chromatin-remodeling
complex INO80 component (9), and loss of YY1 sensitizes
cells to UV damage. Importantly, we found that YY1 and
YY2 had somewhat diﬀerent eﬀects on genes identiﬁed in
two UV gene sets. Correspondingly, YY2 loss antagonized
YY1 loss in survival after UV irradiation. This raises the
possibility that YY2 may contribute to alternative
DNA-repair complexes, similar to the case for Phol that
nucleates distinctive polycomb complexes. Our data par-
ticularly conﬁrm the importance of thrombospondin’s role
in UV response regulation, and reveal a new mechanism
for its regulation (46,59,60). Although CD36 is the
thrombospondin receptor (48,61), to our knowledge its
contribution to UV response has not been previously
investigated. More importantly, CD36 is a particularly
interesting YY1–YY2 target gene given its remarkable dif-
ferential response to YY1 and YY2, and the importance
of its roles in inﬂammation, malaria infection, tumor
growth, uptake of dietary fat, atherogenesis and innate
immune function (62–68). No doubt, all of these processes
may be indirectly under control of YY1 and YY2, which
greatly broadens the scope of physiological functions
whose regulation by YY1 and YY2 deserve increased
attention.
Taken together our data show that YY2 functions as a
gene-expression regulator that may be as important as
YY1 in target selection, which is involved in cellular
activities ranging across proliferation, tissue type determi-
nation and UV response to oxidative phosphorylation.
Unlike Phol, YY2 is not a fully redundant factor of
YY1. It possesses several diﬀerent regulatory target sets,
and for some targets shared with YY1 it can exert
opposite rather than complementary eﬀects. Indeed,
given that YY2 is less abundant than YY1 and shYY2
Figure 7. Gene sets that respond more to shYY2 than shYY1 include UV response genes. (A and B) Enrichment plots of two UV response gene sets
targeted by shYY2 that were not aﬀected by shYY1. These two data sets were derived from genome-wide comparisons of changes in gene expression
in UV-irradiated keratinocytes (45). (C and D) Histogram counts of shYY1 (C) and shYY2 (D) eﬀects on UV sensitive genes were plotted as in
Figures 3 and 5.
4022 Nucleic Acids Research, 2010,Vol.38, No. 12is less eﬀective than shYY1in gene knock down, our data
suggest that YY2 is a more potent regulator than might be
initially expected. Moreover, our data re-assert a role for
YY1 as a Myc regulator, which has received little atten-
tion since its initial description (40,69,70) and show that
YY2 also potently regulates Myc. After the ribosomal
protein set, the Myc-target gene set is the second most
signiﬁcantly altered gene set aﬀected by both YY1 and
YY2 (Table 1). Given that YY1 and YY2 decreased
Myc mRNA by similar amounts (Figure 1B), this result
should be expected. It further raises the question whether
some YY1 and 2 target genes are actually indirect c-Myc
targets. This question is especially important given that
dMyc targets show remarkable overlap with those
regulated by polycomb (71,72). To date this overlap has
not been recapitulated in human cells, but our data show
remarkable parallels to the ﬂy result. In addition, this
YY1–Myc interaction may provide the ﬁrst explanation
for Myc’s tendency to regulate ribosomal protein genes
in the absence of genomic Myc-binding sites in those
genes (73,74). Future interaction studies should begin to
unravel this connection, and continue to identify new
physiologic functions that may be diﬀerentially regulated
by YY1 and its important homolog, YY2.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
Figure 8. shYY1 and shYY2 aﬀect UV damage sensitivity. (A) Cell survival curves after UV exposure. Cells expressing vector control constructs,
shYY1, shYY2 and combined shYY1/2 were exposed to UV radiation as described in methods. Irradiated cells were then plated in a standard
survival curve analysis. Fraction survival at the indicated UV doses was calculated by dividing the cell density measured by MTT for the indicated
dose by the cell density of untreated cells grown for the same time intervals. UV sensitivity is increased in shYY1 normalized in cells expressing both
shYY1 and shYY2. Error bars=standard errors, n=24 for each dose/construct combination. (B) Immunoblots for thrombospondin (THBS1) and
CD36 conﬁrmed that protein changes matched mRNA levels measured by qRT-PCR in Figure 4C and F. The CD36 immunoblot was performed
twice using diﬀering loading amounts and exposure times to highlight the diﬀerences between its levels in lanes 3 and 1 (top CD36) and lanes 4 and 2
(second CD36). Arrows indicate the CD36-speciﬁc band. An actin loading control is shown. (C) qRT-PCR conﬁrms expression changes of
UV-responsive genes aﬀected by shYY1 and shYY2 in HeLa cells. Error bars=SEM, n=3.(D and E) mRNA expression changes were conﬁrmed
using qRT-PCR for three candidate genes in the T47D and MCF7 cells transduced with the knock down constructs. Gene symbols are indicated
along the x-axis and the fold-change for n=3 are shown along the y-axis. We plot the means and SEM for each gene determination. Shown are
T47D cells (D) and MCF7 cells (E).
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